ESMO 2023 | The emerging role of ctDNA analysis and liquid biopsies in oncology

Federica Di Nicolantonio, PhD, University of Torino, Turin, Italy, comments on the future of circulating tumor DNA (ctDNA) and liquid biopsies in solid tumors. There are multiple assays available for liquid biopsies and they are all useful in different contexts; next-generation sequencing (NGS) tumor-informed panels are practical in the minimal residue disease (MRD) setting, whereas fragmentomics have proven to be promising in assessing early cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.